Loading...

HEREDITARY SPASTIC PARAPLEGIA GENE PANEL BY NGS, EDTA BLOOD

image not found

NABL Cap Accredited 

The Hereditary Spastic Paraplegia Gene Panel by NGS, EDTA Blood is a comprehensive genetic test designed to identify mutations associated with various forms of hereditary spastic paraplegia (HSP). It uses advanced Next-Generation Sequencing to analyze multiple genes linked to progressive lower-limb stiffness and weakness. Metropolis Healthcare performs this test with high analytical precision to support early diagnosis and personalized management. This panel helps clinicians understand disease subtype, inheritance pattern, and prognosis for better long-term care.

  • 17 Crores+ Samples Processed
  • World Class Technology Labs
  • 25+ Years of Trust & Experience
  • Free Home Collection

Price: Rs. 20,000.00

Sample Type: EDTA BLOOD

Fasting Not Required


Notes:H1030

Frequently Asked Questions (FAQ's):

What does the Hereditary Spastic Paraplegia Gene Panel include?
This panel analyzes multiple genes associated with hereditary spastic paraplegia using NGS technology at Metropolis Healthcare.

How does Metropolis Healthcare perform this genetic test?
The test uses high-depth NGS sequencing with stringent quality checks to ensure reliable detection of gene mutations.

Who should undergo this test?
Individuals with progressive leg stiffness, gait disturbances, or a family history of HSP may benefit from this test.

Why is genetic testing important for HSP?
It helps confirm the diagnosis, identify the specific subtype, and guide genetic counseling for families.

What sample is required for this panel?
An EDTA blood sample is needed for DNA extraction and sequencing.

How long does Metropolis Healthcare take to provide results?
Turnaround time varies by panel size, but results are typically delivered within a few weeks.

Can this test help with treatment planning?
Yes, identifying the genetic subtype can assist clinicians in tailoring management and rehabilitation strategies.

Is this test useful for family members?
Yes, once a mutation is identified, targeted testing can be offered to relatives for carrier or risk assessment.

OUR corporates PARTNER

Feedback

Patient's Testimonials

Trusted by Thousands

OUR Accreditations

OUR Lab